AU2019317518B2 - Novel MCT4 inhibitors and uses thereof - Google Patents

Novel MCT4 inhibitors and uses thereof Download PDF

Info

Publication number
AU2019317518B2
AU2019317518B2 AU2019317518A AU2019317518A AU2019317518B2 AU 2019317518 B2 AU2019317518 B2 AU 2019317518B2 AU 2019317518 A AU2019317518 A AU 2019317518A AU 2019317518 A AU2019317518 A AU 2019317518A AU 2019317518 B2 AU2019317518 B2 AU 2019317518B2
Authority
AU
Australia
Prior art keywords
mct4
cancer
subject
pharmaceutical composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019317518A
Other languages
English (en)
Other versions
AU2019317518A1 (en
Inventor
Zhimin HUANG
Jay Vadgama
Ke Wu
Yong Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE
Original Assignee
Charles R Drew Univ Of Medicine And Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles R Drew Univ Of Medicine And Science filed Critical Charles R Drew Univ Of Medicine And Science
Publication of AU2019317518A1 publication Critical patent/AU2019317518A1/en
Application granted granted Critical
Publication of AU2019317518B2 publication Critical patent/AU2019317518B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019317518A 2018-04-25 2019-04-25 Novel MCT4 inhibitors and uses thereof Active AU2019317518B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662637P 2018-04-25 2018-04-25
US62/662,637 2018-04-25
PCT/US2019/029192 WO2020033019A2 (en) 2018-04-25 2019-04-25 Novel mct4 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2019317518A1 AU2019317518A1 (en) 2020-12-17
AU2019317518B2 true AU2019317518B2 (en) 2023-05-25

Family

ID=68532786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019317518A Active AU2019317518B2 (en) 2018-04-25 2019-04-25 Novel MCT4 inhibitors and uses thereof

Country Status (7)

Country Link
US (1) US10919878B2 (OSRAM)
EP (1) EP3784650B1 (OSRAM)
JP (1) JP7115671B2 (OSRAM)
CN (1) CN112888673B (OSRAM)
AU (1) AU2019317518B2 (OSRAM)
CA (1) CA3098189C (OSRAM)
WO (1) WO2020033019A2 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544375B2 (en) * 2019-09-05 2026-02-10 The Board Of Trustees Of The Leland Junior University Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
US20240270749A1 (en) 2021-05-21 2024-08-15 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226438A (OSRAM) 1968-12-03 1971-03-31
GB0327734D0 (en) * 2003-11-28 2003-12-31 Novartis Ag Organic compounds
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CN102731413A (zh) * 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
WO2014189152A1 (en) 2013-05-24 2014-11-27 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
JP2017538689A (ja) 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
WO2016118822A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Chromenone inhibitors of monocarboxylate transporters
WO2016118823A1 (en) 2015-01-22 2016-07-28 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
AU2017444054B2 (en) * 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMIN D. STEFFEN, COYLE DONNA L., DAMODARAN KOMATH, BEROZA PAUL, JACOBSON MYRON K.: "Discovery and Structure–Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 54, no. 15, 11 August 2011 (2011-08-11), US , pages 5403 - 5413, XP055248142, ISSN: 0022-2623, DOI: 10.1021/jm200325s *

Also Published As

Publication number Publication date
AU2019317518A1 (en) 2020-12-17
CA3098189A1 (en) 2020-02-13
EP3784650A4 (en) 2022-01-26
EP3784650B1 (en) 2023-09-06
WO2020033019A2 (en) 2020-02-13
CN112888673A (zh) 2021-06-01
CA3098189C (en) 2025-05-13
CN112888673B (zh) 2022-07-29
US20190352282A1 (en) 2019-11-21
WO2020033019A3 (en) 2020-04-02
US10919878B2 (en) 2021-02-16
JP7115671B2 (ja) 2022-08-09
EP3784650C0 (en) 2023-09-06
JP2021522345A (ja) 2021-08-30
EP3784650A2 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
US10919878B2 (en) MCT4 inhibitors and uses thereof
Nagasawa et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme
US20230285363A1 (en) Combination comprising a glucocorticoid and edo-s101
CN104245699B (zh) Nedd8‑活化酶抑制剂和低甲基化剂的投与
Ondrej et al. To live or let die: Unclear task of autophagy in the radiosensitization battle
US20150366884A1 (en) Compositions and methods for cancer therapy
US20250387419A1 (en) Parp inhibitor-resistant patient treated with th-302
US20240197743A1 (en) Wee1 compound for treating uterine serous carcinoma
Song et al. The MEK1/2 inhibitor AZD6244 sensitizes BRAF-mutant thyroid cancer to vemurafenib
Tambunlertchai et al. Investigating silver nanoparticles and resiquimod as a local melanoma treatment
Haefner et al. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
Wolfson et al. Enhancing FTS (Salirasib) efficiency via combinatorial treatment
US20230381119A1 (en) Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents
CA3286442A1 (en) Pharmaceutical composition and use thereof
CN100455289C (zh) 孟德拉明类抗癌药
WO2024193693A1 (zh) 药物组合及其应用
TW202606659A (zh) Ｋｉｆ１８ａ抑制劑治療結直腸癌的用途
HK40112149A (zh) 药物组合及其应用
WO2026002202A1 (zh) Kif18a抑制剂治疗非小细胞肺癌的用途
TW202606673A (zh) Ｋｉｆ１８ａ抑制劑治療乳腺癌的用途
CN119894521A (zh) 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20220043047A (ko) 스핑고신-1-인산 수용체 효능제의 용도
HK40096221A (en) Combination therapy for the treatment of a liver disease
CN117500505A (zh) 用于治疗子宫浆液性癌的wee1化合物
HK1235679B (en) Combination comprising a glucocorticoid and edo-s101

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)